Ni2o's RapidTest© is a semi-finalist for the XPRIZE Rapid Covid Testing Competition
Ni2o RapidTest© is a saliva based test detecting three antibodies with results displayed under 5 minutes. The ni2o RapidTest© has been selected as one of the semi-finalists for the XPRIZE Rapid Covid Testing Competition.
WASHINGTON, Oct. 26, 2020 /PRNewswire-PRWeb/ -- Ni2o, Inc. is pleased to announce that its COVID-19 ni2o RapidTest© has been selected as one of the semi-finalists for the XPRIZE Rapid Covid Testing Competition that has been launched to locate and support innovative testing methodologies to alleviate the global challenges of the coronavirus pandemic. With tests being inaccessible, too expensive or too slow, communities are being forced to shut down. Economies are crippled due to COVID-19.
Ni2o's RapidTest© is composed of a unique package containing an easy to use device accompanied by a smart microfluidic cartridge and a saliva collection tube. The user simply deposits his or her crude saliva into the receptor tube, caps it and places it into the smart cartridge. Then the user inserts the cartridge into the portable device, which quantifies SARS-CoV-2 antibodies - IgG, IgM, and IgA. The whole process takes under 5 minutes to display the results on the device's digital screen. The user can further attach their device to a PC or mobile device via the USB connection to instantly report the results.
The ni2o RapidTest© will be reasonably priced, and, over the long term, our device will easily accommodate other pathogens to test against. As we struggle to return to normal, antibody testing is emerging as an important assessment tool to identify asymptomatic cases, better understand immunity, and identify potential COVID-19 hotspots. The rapid quantification of antibodies provides users an understanding of the stages of infection and immunity they have. Ni2o RapidTest© can detect early, ongoing, or late stage infection, whether or not the user has symptoms. Further, ni2o RapidTest© provides insight into individual differences in immune responses to the virus which will facilitate vaccine development. Ni2o RapidTest© is planned to evolve to a multiplex test platform. For more information visit https://ni2o.com/ni2o-rapidtest/
Ni2o's RapidTest© is a culmination of extensive combined efforts of award winning chemists, engineers, and scientists from the University of Nebraska, Lincoln, Georgetown University, University of Kansas and Oxford University in England.
XPRIZE, a 501(c)(3) nonprofit, is the global leader in designing and implementing innovative competition models to solve the world's grandest challenges. Active competitions include the $20 Million NRG COSIA Carbon XPRIZE, the $10 Million Rainforest XPRIZE, the $10 Million ANA Avatar XPRIZE, the $5 Million IBM Watson AI XPRIZE, $5 Million XPRIZE Rapid Reskilling, XPRIZE NextGen Mask Challenge, and $5 Million XPRIZE Rapid COVID Testing. For more information, visit xprize.org.
Ni2o, Inc. http://www.ni2o.com is a leading neuromodulation and medical device developer and manufacturer that focuses on producing proprietary technologies combining the latest artificial intelligence and scientific discoveries to alleviate society's burden of managing prevalent diseases.
SOURCE Ni2o, Inc.
Share this article